Detailed Narrative
Q1 FY27 Performance Highlights
Windlas Biotech Limited reported its highest ever quarterly revenue of INR 248 crores in Q1 FY27, marking an 18% Y-o-Y growth and the 14th consecutive quarter of record revenue. Excluding ESOP expenses, EBITDA grew 26% Y-o-Y to INR 34 crores, PBT grew 27% Y-o-Y to INR 30 crores, and PAT grew 37% Y-o-Y to INR 25 crores. The company also completed an INR 47 crores buyback and declared an FY26 dividend of INR 13 crores (INR 6.30 per equity share).
Segmental Performance: CDMO and Trade Generics
The Generic Formulations CDMO vertical was a key growth driver, delivering 29% Y-o-Y revenue growth to INR 207 crores, fueled by customer expansion, deeper customer engagement, and new product launches. In contrast, the Trade Generics & Institutional vertical reported revenue of INR 30 crores, impacted by the discontinuation of codeine-based products. Management acknowledged the temporary hit to momentum in this segment but expressed confidence in its long-term potential through portfolio expansion and geographic reach.
Exports Vertical Growth
The Exports vertical demonstrated significant growth, recording 79% Y-o-Y revenue growth to INR 11 crores. Management reiterated its positive outlook for this segment, viewing it as a long-term growth opportunity, despite its higher gestation period. Efforts in strategic partnerships, client diversification, and capability enhancement are expected to continue driving this growth.
Capacity Expansion and Utilization Strategy
The company is on track for the commercialization of Plant 6 in H1 of FY27, which is expected to add INR 1,100 crores in revenue potential. Management emphasized a disciplined approach to capacity expansion, focusing on incremental additions and optimizing existing facilities to achieve 60-65% peak utilization, which can be stretched to 70%. Initial quarterly depreciation from Plant 6 is estimated at approximately INR 30 million starting from Q3 FY27.
API Price Environment and Margin Management
API prices have experienced significant volatility due to crude oil situations and other factors, impacting material availability and pricing. As a cost-plus business, Windlas works closely with its customers to manage these fluctuations, prioritizing consistent supply and output over temporary margin advantages. The company's focus remains on maintaining consistency at a basket level with customers rather than seeking short-term gains from price movements.